- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Supplemental New Drug Application for IMBRUVICA™ (ibrutinib) Submitted to the U.S. FDA
New submission based on positive Phase 3 data from the RESONATE™ trial
Janssen Initiates Phase 3 OPTIMIST Trials of Once-Daily Simeprevir in Combination with Once-Daily Sofosbuvir for the Treatment of Genotype 1 Chronic Hepatitis C
OPTIMIST represents the first Phase 3 studies of the two treatments in a regimen without interferon and ribavirin
Anti-Interleukin-23 Monoclonal Antibody Guselkumab Shows Significant Efficacy In Treatment Of Moderate To Severe Plaque Psoriasis
Results from Phase 2b X-PLORE Study through Week 40 Report Efficacy of Guselkumab across Multiple Dosing Regimens and Compared with Adalimumab
Janssen Investigational Treatment for Schizophrenia Shows Positive Efficacy, Delays Relapse
Independent Data Monitoring Committee Recommends Halting Trial and Unblinding Data Based on Treatment Efficacy
Janssen Initiates CREDENCE Study in Patients with Type 2 Diabetes and Diabetic Nephropathy
Trial Seeks to Examine the Effects of INVOKANA® on the Progression of Diabetic Nephropathy